关键信息
-
基因名
GDN
- 应用
-
别名
SERPINE2; PI7; PN1; PNI; Protease Nexin I; Serpin Peptidase Inhibitor Clade E Member 2; Peptidase inhibitor 7; Protease nexin I
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P07093
-
表达区间
Ser20~Pro398
-
分子量
44kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
GDN (Glial cell-derived neurotrophic factor) is a crucial protein that plays a significant role in the survival, development, and maintenance of neurons. It is part of the GDNF family of neurotrophic factors, which are essential for the health of dopaminergic neurons and have been implicated in various neurological disorders. Research on GDN has garnered substantial interest due to its potential therapeutic applications, particularly in diseases such as Parkinson's disease, where dopaminergic neuron degeneration leads to severe motor dysfunction. Studies have shown that GDN promotes neuron survival and differentiation, suggesting its use in regenerative medicine and neuroprotection strategies. Additionally, GDN interacts with specific receptors, sparking further exploration into its signaling pathways and mechanisms of action. As a result, the recombinant form of GDN has been developed for research and clinical purposes, aiming to uncover its full potential as a neuroprotective agent and its role in neurodegenerative disease treatments. Understanding the molecular basis of GDN's actions could pave the way for innovative therapeutic interventions, providing hope for improved outcomes in patients affected by neurodegenerative conditions. The ongoing research into GDN and its recombinant forms underscores the urgency and importance of elucidating its properties and enhancing its applications in neuroscience and medicine.
